|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Billionaire superinvestors Felix and Julian Baker started buying shares of the beaten-down vaccine maker Novavax in the second quarter.
Supernus (SUPN) decides to stop evaluating the lower dose option of SPN-810 for treatment of impulsive aggression. However, the company will carry on with the study of higher dose arm or placebo.
Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.